NanoBio Corporation is a University of Michigan spinoff that is currently developing a topical lotion containing a nanoscale antimicrobial agent to treat skin infections. The company presented data from its phase one FDA clinical trials at the 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy on September 17 – 20, 2007 in Chicago, Illinois. The data showed the lotion was able to enter skin through pores and hair follicles, but was too large "to penetrate the tight junctions of the epithelium." The data also showed the drug was not systemically absorbed. These results should be of particular interest to those involved in the never-ending nanosuncreen/nanocosmetic EHS debate.
